Tags

Type your tag names separated by a space and hit enter

Neurogenic orthostatic hypotension after treatment with sorafenib.
BMJ Case Rep. 2022 Dec 22; 15(12)BC

Abstract

A man in his 70s with a history of fatigue, abdominal pain, and a palpable abdominal mass was found to have a peritoneal desmoid tumour. One year after diagnosis, he was prescribed sorafenib to limit tumour growth. Two months later, he developed dyspnoea on exertion and lower extremity weakness and was reported to have supine hypertension and orthostatic hypotension. On formal autonomic testing, he was noted to have severely impaired sympathetic responses and marked orthostatic hypotension without appropriate chronotropic response. A decision to hold sorafenib was made, and treatment was started with graduated compression stockings, liberal fluid and sodium intake, and midodrine. The patient had a modest and gradual improvement in his symptoms. To our knowledge, this is the first reported case of orthostatic hypotension related to sorafenib or any vascular endothelial growth factor inhibitors.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Wegner Wippel C
Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA wegnerwippel.cath@gmail.com.
Deshpande H
Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA.
Patwa H
Neurology, Yale School of Medicine, New Haven, Connecticut, USA.
Peixoto AJ
Nephrology, Yale School of Medicine, New Haven, Connecticut, USA.

MeSH

MaleHumansHypotension, OrthostaticSorafenibVascular Endothelial Growth Factor AMidodrineHypertension

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

36549761

Citation

Wegner Wippel, Catherine, et al. "Neurogenic Orthostatic Hypotension After Treatment With Sorafenib." BMJ Case Reports, vol. 15, no. 12, 2022.
Wegner Wippel C, Deshpande H, Patwa H, et al. Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Rep. 2022;15(12).
Wegner Wippel, C., Deshpande, H., Patwa, H., & Peixoto, A. J. (2022). Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Reports, 15(12). https://doi.org/10.1136/bcr-2021-247140
Wegner Wippel C, et al. Neurogenic Orthostatic Hypotension After Treatment With Sorafenib. BMJ Case Rep. 2022 Dec 22;15(12) PubMed PMID: 36549761.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neurogenic orthostatic hypotension after treatment with sorafenib. AU - Wegner Wippel,Catherine, AU - Deshpande,Hari, AU - Patwa,Huned, AU - Peixoto,Aldo J, Y1 - 2022/12/22/ PY - 2024/12/22/pmc-release PY - 2022/12/22/entrez PY - 2022/12/23/pubmed PY - 2022/12/27/medline KW - Cardiovascular system KW - Chemotherapy KW - Peripheral nerve disease JF - BMJ case reports JO - BMJ Case Rep VL - 15 IS - 12 N2 - A man in his 70s with a history of fatigue, abdominal pain, and a palpable abdominal mass was found to have a peritoneal desmoid tumour. One year after diagnosis, he was prescribed sorafenib to limit tumour growth. Two months later, he developed dyspnoea on exertion and lower extremity weakness and was reported to have supine hypertension and orthostatic hypotension. On formal autonomic testing, he was noted to have severely impaired sympathetic responses and marked orthostatic hypotension without appropriate chronotropic response. A decision to hold sorafenib was made, and treatment was started with graduated compression stockings, liberal fluid and sodium intake, and midodrine. The patient had a modest and gradual improvement in his symptoms. To our knowledge, this is the first reported case of orthostatic hypotension related to sorafenib or any vascular endothelial growth factor inhibitors. SN - 1757-790X UR - https://www.unboundmedicine.com/medline/citation/36549761/Neurogenic_orthostatic_hypotension_after_treatment_with_sorafenib_ DB - PRIME DP - Unbound Medicine ER -